Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 2;7(6):ofaa202.
doi: 10.1093/ofid/ofaa202. eCollection 2020 Jun.

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases

Muge Cevik  1   2 , Chloe Orkin  3   4 , Paul E Sax  5   6
Affiliations

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases

Muge Cevik et al. Open Forum Infect Dis. .

Abstract

None of the licensing studies of dolutegravir (DTG) reported any treatment-emergent resistance among DTG-treated individuals, though virological failure in treatment-naïve and treatment-experienced, integrase strand transfer inhibitor (INSTI)-naïve individuals has been reported in clinical practice. While the spectrum of dolutegravir-selected mutations and their effects on clinical outcome have been described, the clinical characteristics of these rare but important virological failure cases are often overlooked. In this perspective piece, we focus on key clinical aspects of emergent resistance to DTG among treatment-naïve and treatment-experienced INSTI-naïve patients, with an aim to inform clinical decision-making. Poor adherence and HIV disease factors contribute to emergent drug resistance, even in regimens with high resistance barriers. Patients with severe immunosuppression or poor adherence are under-represented in licensing studies, and these patients may be at higher risk of treatment failure with DTG resistance, which requires close clinical and laboratory follow-up.

Keywords: HIV; dolutegravir; resistance; treatment failure; treatment-naïve.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rhee SY, Grant PM, Tzou PL, et al. . A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother 2019; 74:3135–49. - PMC - PubMed
    1. Lepik KJ, Harrigan PR, Yip B, et al. . Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS 2017; 31:1425–34. - PubMed
    1. Taiwo BO, Marconi VC, Berzins B, et al. . Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis 2018; 66:1794–7. - PMC - PubMed
    1. Fulcher JA, Du Y, Zhang TH, et al. . Emergence of integrase resistance mutations during initial therapy containing dolutegravir. Clin Infect Dis 2018; 67:791–4. - PMC - PubMed
    1. Pena MJ, Chueca N, D’Avolio A, et al. . Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: rare but possible. Open Forum Infect Dis 2019; 6:XXX–XX. - PMC - PubMed